Canopy Growth (NASDAQ:CGC – Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.
Earnings & Valuation
This table compares Canopy Growth and 60 Degrees Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Canopy Growth | $251.01 million | 1.65 | -$190.29 million | ($0.45) | -2.05 |
| 60 Degrees Pharmaceuticals | $1.41 million | 2.34 | -$7.36 million | ($4.82) | -0.19 |
Volatility & Risk
Canopy Growth has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations for Canopy Growth and 60 Degrees Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Canopy Growth | 1 | 2 | 2 | 0 | 2.20 |
| 60 Degrees Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 1,376.55%. Given 60 Degrees Pharmaceuticals’ higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Canopy Growth.
Profitability
This table compares Canopy Growth and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Canopy Growth | -65.33% | -21.91% | -14.34% |
| 60 Degrees Pharmaceuticals | -650.21% | N/A | -136.81% |
Insider & Institutional Ownership
3.3% of Canopy Growth shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
60 Degrees Pharmaceuticals beats Canopy Growth on 8 of the 14 factors compared between the two stocks.
About Canopy Growth
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
